Karl Sash, MD
Geriatric Medicine · Evansville, INNPI 1902883291
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $22,600 of the $25,650 with a category attached, or 88.1%. 12 manufacturers reported payments, led by Johnson & Johnson at 50.6% of the total. Reporting peaked in 2019 at $20,084 and has fallen 99.9% since, to $15 in 2024. Among geriatric medicine clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 73 payments — averaging $351.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$13K
- Pfizer$12K
- Acadia Pharmaceuticals Inc$136
- Novartis$110
- AMAG Pharmaceuticals, Inc.$93
- AbbVie$81
- plus $155 from 6 others
What the payments were for
- Speaking & faculty fees$22,60088%
- Travel & lodging$1,5116%
- Food & beverage$1,5396%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 28 | $12,982 |
| Pfizer | 26 | $12,093 |
| Acadia Pharmaceuticals Inc | 2 | $136 |
| Novartis | 5 | $110 |
| AMAG Pharmaceuticals, Inc. | 1 | $93 |
| AbbVie | 1 | $81 |
| Sunovion Pharmaceuticals Inc. | 4 | $68 |
| Amgen | 2 | $34 |
| Novo Nordisk | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| GSK | 1 | $12 |
| Lilly USA, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVOKANA$12,502
- COLOGUARD$10,020
- COLOGUARD DNA CAPTURE REAGENTS$1,900
- XARELTO$236
How this compares
$25,650 in reported general payments places this provider in the 95th percentile of 70 geriatric medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 304 | $130,643 |
| XareltoRivaroxaban | 103 | $45,525 |
| MyrbetriqMirabegron | 102 | $29,996 |
| JardianceEmpagliflozin | 28 | $23,096 |
| TrulicityDulaglutide | 18 | $18,170 |
| FarxigaDapagliflozin Propanediol | 37 | $16,882 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $16,878 |
| OzempicSemaglutide | 15 | $14,129 |
| GemtesaVibegron | 45 | $13,536 |
| Memantine Hcl | 182 | $9,089 |
| RexultiBrexpiprazole | 12 | $7,629 |
| LinzessLinaclotide | 11 | $6,884 |
| Spiriva RespimatTiotropium Bromide | 12 | $6,696 |
| JanuviaSitagliptin Phosphate | 16 | $6,620 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 26 | $6,376 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $12,093 | $130,643304 claims |
| Johnson & JohnsonXarelto | $12,982 | $45,525103 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $15 | $29,79240 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $12 | $20,92746 claims |
| Lilly USA, LLCTrulicity | $11 | $18,17018 claims |
| Novo NordiskOzempic | $16 | $14,12915 claims |
| AbbVieLinzess, Lumigan | $81 | $12,31131 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 70 geriatric medicine providers in Indiana.
Other geriatric medicine in Evansville
- Sarah VolkmanEvansville$1K
- della EvansEvansville$1K
- William HardestyEvansville$62
- Robert FicaloraEvansville$14
- Malaz BoustaniIndianapolis$188K
- Gregory SpanglerKokomo$31K
- Jodie HarperIndianapolis$27K
- Arnold del PilarMishawaka$25K
- Lauren DandurandMerrillville$11K
- Jack BartoszekMishawaka$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.